Prognostic indicators for undifferentiated carcinoma with/without osteoclast-like giant cells of the pancreas
Copyright © 2022 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved..
BACKGROUND: Undifferentiated carcinoma of the pancreas (UPC) is a rare malignancy. There are no standardized guidelines for treatment. Current management has been extrapolated from smaller reviews.
METHODS: 858 patients with UPC were identified in the 2004-2017 NCDB. Kaplan-Meier method followed by Cox proportional-hazards regression examined independent prognostic factors associated with overall survival (OS). Logistic regression analyses were performed to determine independent predictors of surgical intervention and the status of surgical resection by histologic subtype.
RESULTS: Patients with osteoclast-like giant cells (OCLGC) had a longer median OS compared to those without (aHR 0.52: 95% CI 0.41-0.67). Of the non-OCLGC subtypes, pleomorphic large cell demonstrated the shortest median OS (2.4 months). Surgical resection was associated with improved survival in all histologies except for pleomorphic cell carcinoma. R0 resection and negative lymph nodes were independently associated with an improved OS.
CONCLUSION: This is the largest database review published to date on UCP. OCLGC histology is associated with an improved survival compared to those without OCLGC. Of the non-OCLGC subtypes, pleomorphic large cell is associated with the shortest overall survival. Surgical resection is associated with a significant survival advantage for all histologies except for pleomorphic cell carcinoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
HPB : the official journal of the International Hepato Pancreato Biliary Association - 24(2022), 10 vom: 01. Okt., Seite 1757-1769 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Christopher, Wade [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 25.10.2022 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.hpb.2022.05.1344 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343007908 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343007908 | ||
| 003 | DE-627 | ||
| 005 | 20231227130836.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.hpb.2022.05.1344 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM343007908 | ||
| 035 | |a (NLM)35780038 | ||
| 035 | |a (PII)S1365-182X(22)01491-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Christopher, Wade |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic indicators for undifferentiated carcinoma with/without osteoclast-like giant cells of the pancreas |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.10.2022 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Undifferentiated carcinoma of the pancreas (UPC) is a rare malignancy. There are no standardized guidelines for treatment. Current management has been extrapolated from smaller reviews | ||
| 520 | |a METHODS: 858 patients with UPC were identified in the 2004-2017 NCDB. Kaplan-Meier method followed by Cox proportional-hazards regression examined independent prognostic factors associated with overall survival (OS). Logistic regression analyses were performed to determine independent predictors of surgical intervention and the status of surgical resection by histologic subtype | ||
| 520 | |a RESULTS: Patients with osteoclast-like giant cells (OCLGC) had a longer median OS compared to those without (aHR 0.52: 95% CI 0.41-0.67). Of the non-OCLGC subtypes, pleomorphic large cell demonstrated the shortest median OS (2.4 months). Surgical resection was associated with improved survival in all histologies except for pleomorphic cell carcinoma. R0 resection and negative lymph nodes were independently associated with an improved OS | ||
| 520 | |a CONCLUSION: This is the largest database review published to date on UCP. OCLGC histology is associated with an improved survival compared to those without OCLGC. Of the non-OCLGC subtypes, pleomorphic large cell is associated with the shortest overall survival. Surgical resection is associated with a significant survival advantage for all histologies except for pleomorphic cell carcinoma | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Nassoiy, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Marcus, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Keller, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Shu-Ching |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Trevan |e verfasserin |4 aut | |
| 700 | 1 | |a Bilchik, Anton |e verfasserin |4 aut | |
| 700 | 1 | |a Goldfarb, Melanie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HPB : the official journal of the International Hepato Pancreato Biliary Association |d 2001 |g 24(2022), 10 vom: 01. Okt., Seite 1757-1769 |w (DE-627)NLM178147761 |x 1477-2574 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:10 |g day:01 |g month:10 |g pages:1757-1769 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.hpb.2022.05.1344 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2022 |e 10 |b 01 |c 10 |h 1757-1769 | ||